Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML

Abstract: The ETAL-1 trial demonstrated that upfront allogeneic hematopoietic stem cell transplant (HSCT) improved disease-free survival, but not overall survival, when compared with consolidation chemotherapy followed by “delayed” HSCT on relapse in patients with intermediate-risk acute myeloid leu...

Full description

Bibliographic Details

Published in:	Blood Advances
Main Authors:	Abdulrahman Alhajahjeh, Kishan K. Patel, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Stuart Seropian, Lohith Gowda, Scott F. Huntington, Maximilian Stahl, Amer M. Zeidan, George Goshua, Jan Philipp Bewersdorf
Format:	Article
Language:	English
Published:	Elsevier 2025-10-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2473952925004446